# Hemotune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hemotune

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.hemotune.ch
- Total disclosed funding: $23M
- Latest round: Series B (Mar 25, 2024)
- Investors on record: 7

## About

Founded in 2017 and based in Zurich, Switzerland, Hemotune AG operates as a biotechnology company. The firm is a spin-off company originating from the Functional Materials Lab at ETH Zurich. The company was founded by its CEO, Lukas Langenegger, and CTO Carlos Mora. In March 2024, Hemotune AG raised CHF 14 million in series B funding led by Belmondo, EFI Lake Geneva Ventures, Occident Group, and Zürcher Kantonalbank.

Hemotune offers a blood purification platform using magnetic beads to treat conditions like sepsis, infections, and autoimmune diseases by restoring blood balance. The firm’s product line includes a HemoDevice, which is a purification device; HemoDisposable, a sterile single-use disposable tubing set; and HemoSorbent, a single-use product containing tiny magnetic beads.

The company plans to use the funds raised in March 2024 for the conduct of clinical trials for its HemoSystem breakthrough blood purification platform.

## Funding rounds

- Series B, Mar 25, 2024, $16M — Zürcher Kantonalbank, Hemex AG, Efficient Frontier Investing, Occident Group, VP Venture Partners, Belmondo
- Series B, Apr 26, 2022, $7.5M — Zürcher Kantonalbank, Occident Group, Hemex AG, VP Venture Partners
- Seed, Jun 21, 2017, $0.1M — Venture Kick

## Investors

- Venture Kick (https://capitalatlas.ai/funds/venture-kick) — Seed
- Zürcher Kantonalbank — Series B
- Occident Group — Series B
- Hemex AG (https://capitalatlas.ai/funds/hemex-ag) — Series B
- VP Venture Partners (https://capitalatlas.ai/funds/vp-venture-partners) — Series B
- Efficient Frontier Investing (https://capitalatlas.ai/funds/efficient-frontier-investing) — Series B
- Belmondo — Series B